Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Viate Pharmaceuticals Inc (VTAE) A Good Stock To Buy?

Page 1 of 2

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn’t mean that they don’t have occasional colossal losses; they do (like Ackman’s recent Valeant losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let’s examine the smart money sentiment towards Viate Pharmaceuticals Inc (NASDAQ:VTAE).

Viate Pharmaceuticals Inc (NASDAQ:VTAE)’s shares plunged by 20% in the third quarter, but the number of bullish hedge fund bets went up by six and a total of 15 funds among those we track reported long positions in the biotech company as of the end of September. At the end of this article we will also compare VTAE to other stocks, including Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), Ares Dynamic Credit Allocation Fund Inc (NYSE:ARDC), and McEwen Mining Inc (NYSE:MUX) to get a better sense of its popularity.

Follow Vitae Pharmaceuticals Inc (NASDAQ:VTAE)
Trade (NASDAQ:VTAE) Now!

To most market participants, hedge funds are assumed to be slow, outdated investment tools of the past. While there are more than 8000 funds trading at present, Our researchers choose to focus on the bigwigs of this group, approximately 700 funds. Most estimates calculate that this group of people handle bulk of all hedge funds’ total asset base, and by tailing their best equity investments, Insider Monkey has unearthed numerous investment strategies that have historically exceeded Mr. Market. Insider Monkey’s small-cap hedge fund strategy defeated the S&P 500 index by 12 percentage points annually for a decade in their back tests.

With all of this in mind, let’s take a look at the fresh action regarding Viate Pharmaceuticals Inc (NASDAQ:VTAE).

Hedge fund activity in Viate Pharmaceuticals Inc (NASDAQ:VTAE)

At the end of the third quarter, a total of 15 of the hedge funds tracked by Insider Monkey held long positions in this stock, an increase of 67% from one quarter earlier. Among these investors, Biotechnology Value Fund / BVF Inc, managed by Mark Lampert, holds the most valuable position in Viate Pharmaceuticals Inc (NASDAQ:VTAE). BVF Inc has a $26.2 million position in the stock, comprising 5.3% of its 13F portfolio. The second most bullish fund is Phill Gross and Robert Atchinson’s Adage Capital Management, with a $15.8 million position; less than 0.1%% of its 13F portfolio is allocated to the company. Some other members of the smart money that hold long positions encompass Israel Englander’s Millennium Management, Steve Cohen’s Point72 Asset Management, and Samuel Isaly’s OrbiMed Advisors.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!